Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Murciano-Goroff YR et al.
Clinical and Translational Medicine, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping.
Bogdanska W et al.
Cancer, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Elife, 2025
Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.
Lin H et al.
Communications Biology, 2025
Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO et al.
Biorxiv : the Preprint Server for Biology, 2024
Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.
Bumpers QA et al.
Journal of Medicinal Chemistry, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A et al.
Biomarker Research, 2024
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.
Iweala EEJ et al.
Current Research in Pharmacology and Drug Discovery, 2024
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G et al.
Cancers, 2023
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R et al.
Cancers, 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer.
Zhou J et al.
Signal Transduction and Targeted Therapy, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report.
Choi W et al.
Translational Lung Cancer Research, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Bahcall M et al.
Molecular Cancer Therapeutics, 2022
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease.
Blaquier JB et al.
Drugs in Context, 2022
Meeting an un-MET need: Targeting MET in non-small cell lung cancer.
Michaels E et al.
Frontiers in Oncology, 2022
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
Cheema PK et al.
Current Oncology (toronto, Ont.), 2021
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM et al.
Journal of Hematology & Oncology, 2021
Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
Kim CG et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.
Santarpia M et al.
Translational Lung Cancer Research, 2021
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges.
Fujino T et al.
Lung Cancer (auckland, N.z.), 2021
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].
Unknown Author
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020
Meta-analysis of functional expression and mutational analysis of c-Met in various cancers.
Sivakumar M et al.
Current Problems in Cancer, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C et al.
Current Treatment Options in Oncology, 2020
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Non-small cell lung cancer with mesenchymal-epithelial transition gene exon 14 skipping mutation treated with crizotinib.
Katakura S et al.
Respirology Case Reports, 2019
Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
Chuang YC et al.
Scientific Reports, 2019
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.
Shen B et al.
Future Oncology (london, England), 2019
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Engstrom LD et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.
Lu X et al.
Cancer Research, 2017
Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J et al.
Oncotarget, 2017